ABSTRACT
Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy that may involve skin, nails, axial-peripheral joints and entesial regions. The course of the disease is diverse. As the knowledge and awareness of PsA are growing day by day, treatment options are also increasing in number. New members of conventional disease-modifying antirheumatic drug family, anti- tumor necrosis factor agents, interleukin-17 blockers, inhibitors of IL-12/23 pathway, T-cell modulators and janus kinase inhibitors are currently available options for the medical treatment of PsA. In this article, we focused on the route and dose of administration, efficacy and safety of these agents.
References
1Kingsley GH, Kowalczyk A, Taylor H, et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford) 2012;51:1368-77.
2Gossec L, Smolen JS, Ramiro S, et al. European league against rheumatism (eular) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 2016;75:499-510.
3Coates LC, Gossec L, Ramiro S, et al. New grappa and eular recommendations for the management of psoriatic arthritis. Rheumatology (Oxford) 2017;56:1251-3.
4Coates LC, Helliwell PS. Methotrexate efficacy in the tight control in psoriatic arthritis study. J Rheumatol 2016;43:356-61.
5Kaltwasser JP, Nash P, Gladman D, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: A multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2004;50:1939-50.
6Schett G, Wollenhaupt J, Papp K, et al. Oral apremilast in the treatment of active psoriatic arthritis: Results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2012;64:3156-67.
7Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis 2014;73:1020-6.
8Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to tnf inhibitors. N Engl J Med 2017;377:1525-36.
9Mease P, Coates LC, Helliwell PS, et al. Efficacy and safety of filgotinib, a selective janus kinase 1 inhibitor, in patients with active psoriatic arthritis (equator): Results from a randomised, placebo-controlled, phase 2 trial. Lancet 2018;392:2367-77.
10Orbai AM, Weitz J, Siegel EL, et al. Systematic review of treatment effectiveness and outcome measures for enthesitis in psoriatic arthritis. J Rheumatol 2014;41:2290-4.
11Saad AA, Symmons DP, Noyce PR, Ashcroft DM. Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: Systematic review and metaanalysis of randomized controlled trials. J Rheumatol 2008;35:883-90.
12Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial. Lancet 2000;356:385-90.
13Van Den Bosch F, Kruithof E, Baeten D, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum 2002;46:755-65.
14Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:3279-89.
15Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009;60:976-86.
16Mease PJ, Fleischmann R, Deodhar AA, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a phase 3 double-blind randomised placebo-controlled study (rapid-psa). Ann Rheum Dis 2014;73:48-55.
17Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50:2264-72.
18Mease PJ, Kivitz AJ, Burch FX, et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol 2006;33:712-21.
19Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (impact). Arthritis Rheum 2005;52:1227-36.
20Gladman DD, Mease PJ, Choy EH, Ritchlin CT, Perdok RJ, Sasso EH. Risk factors for radiographic progression in psoriatic arthritis: Subanalysis of the randomized controlled trial adept. Arthritis Res Ther 2010;12:R113.
21Kavanaugh A, van der Heijde D, McInnes IB, et al. Golimumab in psoriatic arthritis: One-year clinical efficacy, radiographic, and safety results from a phase iii, randomized, placebo-controlled trial. Arthritis Rheum 2012;64:2504-17.
22van der Heijde D, Fleischmann R, Wollenhaupt J, et al. Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: Results of the rapid-psa 24-week phase iii double-blind randomised placebo-controlled study of certolizumab pegol. Ann Rheum Dis 2014;73:233-7.
23Glintborg B, Ostergaard M, Dreyer L, et al. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor alpha therapy: Results from the nationwide danish danbio registry. Arthritis Rheum 2011;63:382-90.
24Goulabchand R, Mouterde G, Barnetche T, Lukas C, Morel J, Combe B. Effect of tumour necrosis factor blockers on radiographic progression of psoriatic arthritis: A systematic review and meta-analysis of randomised controlled trials. Ann Rheum Dis 2014;73:414-9.
25Yun H, Xie F, Delzell E, et al. Comparative risk of hospitalized infection associated with biologic agents in rheumatoid arthritis patients enrolled in medicare. Arthritis Rheumatol 2016;68:56-66.
26Khoury SJ, Rochon J, Ding L, et al. Acclaim: A randomized trial of abatacept (ctla4-ig) for relapsing-remitting multiple sclerosis. Mult Scler 2017;23:686-95.
27Mease PJ, Gottlieb AB, van der Heijde D, et al. Efficacy and safety of abatacept, a t-cell modulator, in a randomised, double-blind, placebo-controlled, phase iii study in psoriatic arthritis. Ann Rheum Dis 2017;76:1550-8.
28Mease PJ, McInnes IB, Kirkham B, et al. Secukinumab inhibition of interleukin-17a in patients with psoriatic arthritis. N Engl J Med 2015;373:1329-39.
29McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17a monoclonal antibody, in patients with psoriatic arthritis (future 2): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015;386:1137-46.
30Mease PJ, van der Heijde D, Ritchlin CT, et al. Ixekizumab, an interleukin-17a specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: Results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase iii trial spirit-p1. Ann Rheum Dis 2017;76:79-87.
31Nash P, Kirkham B, Okada M, et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: Results from the 24-week randomised, double-blind, placebo-controlled period of the spirit-p2 phase 3 trial. Lancet 2017;389:2317-27.
32Mease PJ, Genovese MC, Greenwald MW, et al. Brodalumab, an anti-il17ra monoclonal antibody, in psoriatic arthritis. N Engl J Med 2014;370:2295-306.
33Sherlock JP, Joyce-Shaikh B, Turner SP, et al. Il-23 induces spondyloarthropathy by acting on ror-gammat+ cd3+cd4-cd8- entheseal resident t cells. Nat Med 2012;18:1069-76.
34McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled psummit 1 trial. Lancet 2013;382:780-9.
35Ritchlin C, Rahman P, Kavanaugh A, et al. Efficacy and safety of the anti-il-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised psummit 2 trial. Ann Rheum Dis 2014;73:990-9.
36Spadaro A, Montepaone M, Lubrano E. A novel biological target for the treatment of psoriatic arthritis. Immunotherapy 2014;6:515-8.
37Deodhar A, Gottlieb AB, Boehncke WH, et al. Efficacy and safety of guselkumab in patients with active psoriatic arthritis: A randomised, double-blind, placebo-controlled, phase 2 study. Lancet 2018;391:2213-24.
